These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 30092774)

  • 1. An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany.
    Borisenko O; Müller-Ehmsen J; Lindenfeld J; Rafflenbeul E; Hamm C
    BMC Cardiovasc Disord; 2018 Aug; 18(1):163. PubMed ID: 30092774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States.
    Bisognano J; Schneider JE; Davies S; Ohsfeldt RL; Galle E; Stojanovic I; Deering TF; Lindenfeld J; Zile MR
    BMC Cardiovasc Disord; 2021 Mar; 21(1):155. PubMed ID: 33771104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis in Telehealth: A Comparison between Home Telemonitoring, Nurse Telephone Support, and Usual Care in Chronic Heart Failure Management.
    Grustam AS; Severens JL; De Massari D; Buyukkaramikli N; Koymans R; Vrijhoef HJM
    Value Health; 2018 Jul; 21(7):772-782. PubMed ID: 30005749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Barostim therapy for the treatment of resistant hypertension in European settings.
    Borisenko O; Beige J; Lovett EG; Hoppe UC; Bjessmo S
    J Hypertens; 2014 Mar; 32(3):681-92. PubMed ID: 24378998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
    Pradelli L; Iannazzo S; Zaniolo O
    Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction.
    Weaver FA; Abraham WT; Little WC; Butter C; Ducharme A; Halbach M; Klug D; Lovett EG; Madershahian N; Müller-Ehmsen J; Schafer JE; Senni M; Swarup V; Wachter R; Zile MR
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):320-328. PubMed ID: 28043438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of cardiac resynchronization therapy in combination with an implantable cardioverter defibrillator (CRT-D) for the treatment of chronic heart failure from a German health care system perspective.
    Aidelsburger P; Grabein K; Klauss V; Wasem J
    Clin Res Cardiol; 2008 Feb; 97(2):89-97. PubMed ID: 17955159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure.
    Mealing S; Woods B; Hawkins N; Cowie MR; Plummer CJ; Abraham WT; Beshai JF; Klein H; Sculpher M
    Heart; 2016 Nov; 102(21):1742-1749. PubMed ID: 27411837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimisation of cardiac resynchronisation therapy device selection guided by cardiac magnetic resonance imaging: Cost-effectiveness analysis.
    Crespo C; Linhart M; Acosta J; Soto-Iglesias D; Martínez M; Jáuregui B; Mira Á; Restovic G; Sagarra J; Auricchio A; Fahn B; Boltyenkov A; Lasalvia L; Sampietro-Colom L; Berruezo A
    Eur J Prev Cardiol; 2020 Apr; 27(6):622-632. PubMed ID: 31487998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-utility analysis of percutaneous mitral valve repair in inoperable patients with functional mitral regurgitation in German settings.
    Borisenko O; Haude M; Hoppe UC; Siminiak T; Lipiecki J; Goldberg SL; Mehta N; Bouknight OV; Bjessmo S; Reuter DG
    BMC Cardiovasc Disord; 2015 May; 15():43. PubMed ID: 25971307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baroreflex activation therapy in patients with heart failure with reduced ejection fraction: a single-centre experience.
    Blanco C; Madej T; Mangner N; Hommel J; Grimm S; Knaut M; Linke A; Winzer EB
    ESC Heart Fail; 2023 Dec; 10(6):3373-3384. PubMed ID: 37667319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Evaluation of Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure With Reduced Ejection Fraction.
    Chew DS; Loring Z; Anand J; Fudim M; Lowenstern A; Rymer JA; Weimer KED; Atwater BD; DeVore AD; Exner DV; Noseworthy PA; Yancy CW; Mark DB; Piccini JP
    Circ Cardiovasc Qual Outcomes; 2020 Dec; 13(12):e007094. PubMed ID: 33280436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction).
    Linde C; Mealing S; Hawkins N; Eaton J; Brown B; Daubert JC;
    Eur Heart J; 2011 Jul; 32(13):1631-9. PubMed ID: 21112898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost effectiveness of REACH-HF and home-based cardiac rehabilitation compared with the usual medical care for heart failure with reduced ejection fraction: A decision model-based analysis.
    Taylor RS; Sadler S; Dalal HM; Warren FC; Jolly K; Davis RC; Doherty P; Miles J; Greaves C; Wingham J; Hillsdon M; Abraham C; Frost J; Singh S; Hayward C; Eyre V; Paul K; Lang CC; Smith K
    Eur J Prev Cardiol; 2019 Aug; 26(12):1252-1261. PubMed ID: 30884975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy.
    Zile MR; Abraham WT; Weaver FA; Butter C; Ducharme A; Halbach M; Klug D; Lovett EG; Müller-Ehmsen J; Schafer JE; Senni M; Swarup V; Wachter R; Little WC
    Eur J Heart Fail; 2015 Oct; 17(10):1066-74. PubMed ID: 26011593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Value and Cost-Effectiveness of Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure: Projections From the REVERSE Long-Term Follow-Up.
    Gold MR; Padhiar A; Mealing S; Sidhu MK; Tsintzos SI; Abraham WT
    JACC Heart Fail; 2017 Mar; 5(3):204-212. PubMed ID: 28254126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of a cardiac contractility modulation device in heart failure with normal QRS duration.
    Witte K; Hasenfuss G; Kloppe A; Burkhoff D; Green M; Moss J; Peel A; Mealing S; Durand Zaleski I; Cowie MR
    ESC Heart Fail; 2019 Dec; 6(6):1178-1187. PubMed ID: 31997539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-utility analysis of an implantable cardioverterdefibrillator for the treatment of patients with ischemic or non-ischemic New York Heart Association class II or III heart failure in Colombia.
    Atehortúa S; Senior JM; Castro P; Ceballos M; Saldarriaga C; Giraldo N; Mora G
    Biomedica; 2019 Sep; 39(3):502-512. PubMed ID: 31584764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure.
    Nichol G; Kaul P; Huszti E; Bridges JF
    Ann Intern Med; 2004 Sep; 141(5):343-51. PubMed ID: 15353425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction.
    Zile MR; Lindenfeld J; Weaver FA; Zannad F; Galle E; Rogers T; Abraham WT
    J Am Coll Cardiol; 2020 Jul; 76(1):1-13. PubMed ID: 32616150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.